Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332975 · ClinicalTrials.gov registry record
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
A clinical trial, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 77
- Enrollment target
NCT07332975: Recruiting study, sponsored by University of Pittsburgh.
NCT07332975 is a clinical trial that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07332975 is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 77 participants
- Enrollment target
Study Summary
This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
Primary Outcome
Detection of ctDNA by assay in blood collected prior to radical prostatectomy using the Vogelstein lab assay. This assay is a highly sensitive, tumor-informed method of detecting circulating free DNA (cfDNA) shed by solid tumors. This assay has shown prognostic value for recurrence and predictive for benefit of adjuvant chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2029-01-20 |
What NCT07332975 shows while recruiting
NCT07332975 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 77 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07332975 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07332975 about?
NCT07332975 is a clinical study titled "ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC". This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.
What is the current status of trial NCT07332975?
This trial is currently recruiting. The enrollment target is 77 participants. The study started on 2026-01-20. Estimated completion is 2029-01-20.
Who is sponsoring clinical trial NCT07332975?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI